Evidence map›Paper›PMID 35230496›Full record

ArticleApplied microbiology and biotechnology2022

Bioengineering of Halobacterium sp. NRC-1 gas vesicle nanoparticles with GvpC fusion protein produced in E. coli.

Jong-Myoung Kim, Youn-Sook Kim, Yeo-Reum Kim, Mi-Jin Choi, Priya DasSarma, Shiladitya DasSarma

Erratum issuedOpen access · bronzeAbstract read
In one paragraph

Article in Applied microbiology and biotechnology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.4field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Truly tiny acoustic biomolecules for ultrasound imaging and therapy.bioRxiv : the preprint server for biology · 2023
    Article
  5. Article
  6. Review
  7. Modification of PEG reduces the immunogenicity of biosynthetic gas vesicles.Frontiers in bioengineering and biotechnology · 2023
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 2 countries.

Jong-Myoung KimDepartment of Fisheries Biology, PuKyong National University, Busan, 48513, Korea. jongkim@pknu.ac.kr.ORCID http://orcid.org/0000-0003-1005-0952
Youn-Sook KimDepartment of Fisheries Biology, PuKyong National University, Busan, 48513, Korea.ORCID http://orcid.org/0000-0002-6939-0081
Yeo-Reum KimDepartment of Fisheries Biology, PuKyong National University, Busan, 48513, Korea.ORCID http://orcid.org/0000-0003-0318-3319
Mi-Jin ChoiDepartment of Fisheries Biology, PuKyong National University, Busan, 48513, Korea.ORCID http://orcid.org/0000-0003-3537-6182
Priya DasSarmaDepartment of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, MD, USA.ORCID http://orcid.org/0000-0002-7617-8417
Shiladitya DasSarmaDepartment of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, MD, USA. sdassarma@som.umaryland.edu.ORCID http://orcid.org/0000-0003-4162-2810
Pukyong National University · KRPusan National University · KRUniversity of Mary · USUniversity of Maryland, Baltimore · US

Funding

ARCHAEAL-DERIVED SELF ADJUVANTING NANOPARTICLE MALARIA VACCINER21AI139808 · NIAID · JOHNS HOPKINS UNIVERSITY · PI SRINIVASAN, PRAKASH · 2019 to 2020
$457k
KNRF NRF-2017R1D1A1A02019244NIAID NIH HHS R21 AI139808NIH HHS AI139808
6 · The paper itself

Abstract

Gas vesicle nanoparticles (GVNPs) are hollow, buoyant prokaryotic organelles used for cell flotation. GVNPs are encoded by a large gas vesicle protein (gvp) gene cluster in the haloarchaeon, Halobacterium sp. NRC-1, including one gene, gvpC, specifying a protein bound to the surface of the nanoparticles. Genetically engineered GVNPs in the Halobacterium sp. have been produced by fusion of foreign sequences to gvpC. To improve the versatility of the GVNP platform, we developed a method for displaying exogenously produced GvpC fusion proteins on the haloarchaeal nanoparticles. The streptococcal IgG-binding protein domain was fused at or near the C-terminus of GvpC, expressed and purified from E. coli, and shown to bind to wild-type GVNPs. The two fusion proteins, GvpC3GB and GvpC4GB, without or with a highly acidic GvpC C-terminal region, were found to be able to bind nanoparticles equally well. The GVNP-bound GvpC-IgG-binding fusion protein was also capable of binding to an enzyme-linked IgG-HRP complex which retained enzyme activity, demonstrating the hybrid system capability for display and delivery of protein complexes. This is the first report demonstrating functional binding of exogenously produced GvpC fusion proteins to wild-type haloarchaeal GVNPs which significantly expands the capability of the platform to produce bioengineered nanoparticles for biomedical applications. KEY POINTS: • Haloarchaeal gas vesicle nanoparticles (GVNPs) constitute a versatile display system. • GvpC-streptococcal IgG-binding fusion proteins expressed in E. coli bind to GVNPs. • IgG-binding proteins displayed on floating GVNPs bind and display IgG-HRP complex.

Indexed as

HalobacteriumNanoparticlesBacterial ProteinsBioengineeringEscherichia coliOrganellesBacterial ProteinsGas vesicleGVNPHalobacteriumTarget displayTherapy deliveryVaccine

Identifiers

PMID35230496
PMCPMC8885775
OpenAlexW4214562444

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.